ADVA
ADVA (FSE: ADV) today launched its FSP 3000 OpenFabric1200™ solution to help network operators significantly reduce metro costs. The OTN-based technology enables client services to be groomed into 400Gbit/s wavelengths, maximizing fiber capacity and supporting cost-efficient coherent networks. The latest member of the FSP 3000 OpenFabric™ Series combines open 400Gbit/s pluggable coherent technology with OTN switching on a blade, increasing wavelength efficiency. The open switchponder card can be added to any network without requiring additional adaptors. Specifically engineered for the 400Gbit/s era, the ADVA FSP 3000 OpenFabric1200™ features 1200Gbit/s interface capacity and supports Ethernet and OTN services from 10Gbit/s to 400Gbit/s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005220/en/
“The strain on today’s transport infrastructure is growing like never before. Today’s operators need new solutions that can meet rapidly rising data demand while also driving down costs. That’s why we’ve developed our FSP 3000 OpenFabric1200™ . It offers a simple way to dramatically increase fiber efficiency by supporting lower-speed service grooming at the network edge. By deploying OpenFabric1200™ in ring or hub-and-spoke topologies, operators can significantly reduce switching and cross-connect requirements in the core,” said Christoph Glingener, CTO, ADVA. “What’s more, our open Terabit-scale switchponder solution can be easily added to any network.”
The new technology is part of the ADVA FSP 3000 OpenFabric™ Series, a family of switchponders built for maximum openness, flexibility and scale. The OpenFabric1200™ offers OTN switching with the benefits of open CFP2 pluggable coherent interfaces. With Terabit capacity, the new card is the ideal tool for leveraging more value from deployed metro infrastructure and upgrading legacy networks to the latest coherent pluggable technology. The FSP 3000 OpenFabric1200™ can work in multiple operation modes: ADM on a blade, DWDM muxponders, or OTN cross-connect. What’s more, thanks to its open design, client services can be connected directly or via standard OTN-based transponders without the need for any adapters.
“Our FSP 3000 OpenFabric1200™ will be a key tool in tackling skyrocketing bandwidth demand while supporting existing low-speed services. The technology takes our OpenFabric™ concept to the next level, enabling traffic grooming at the edge where it’s most efficient and delivering 1.2Tbit/s interface capacity. It offers the power to adapt to changing traffic demands without a hardware upgrade while simplifying operations and enabling network operators to scale as and when needed,” commented Cornelius Fürst, director, product line management, ADVA. “Our FSP 3000 OpenFabric1200™ is the flexible OTN solution that’s about to switch things up. For metro network operators, our new switchponder opens the door to the benefits of disaggregated environments and the latest pluggable coherent 400Gbit/s technology.”
Watch this video for more information on the FSP 3000 OpenFabric1200™: https://youtu.be/ti101PI1fxw .
Further details are also available in these slides: https://adva.li/fsp-3000-openfabric1200-slides .
A supporting solution brief can be downloaded here: https://adva.li/fsp-3000-openfabric-series-solution-brief .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005220/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alta Semper Signs Definitive Agreements to Acquire a Majority Stake in Nature’s Rule, a MENA-Focused Leader in Dietary Supplements and Sports Nutrition19.1.2026 09:13:00 CET | Press release
Alta Semper, a London-based private equity firm focused on healthcare and consumer investments across growth markets, today announced that it has signed definitive agreements to acquire a majority stake in Nature’s Rule, a leading sports nutrition and dietary supplements company headquartered in the UAE, with an established manufacturing presence in Egypt. The acquisition is a majority investment in Prowell Holding, the parent company of Nature’s Rule, the operator of the largest fully dedicated sports nutrition and dietary supplements manufacturing facility in MENA. The company’s infrastructure and in-house R&D capabilities support a portfolio of private-label clients and proprietary brands, including Redrex, its flagship, market-leading sports nutrition brand developed in collaboration with global bodybuilding icon Mamdouh Elssbiay (“Big Ramy”). The founders will retain a significant stake and continue to lead the business. The partnership will execute a focused value-creation plan t
The UK Chooses Bridge Over Troubled Water as the Nation’s Favourite Song of Hope in Solidarity With Refugees19.1.2026 09:00:00 CET | Press release
Simon and Garfunkel classic named the UK’s top #HopeHitOver 1000 people from across the country nominated songs to show their solidarity with refugees around the world this winterThe most popular Hope Hits available on the Hope On Repeat playlist to get you through Blue Monday Simon and Garfunkel’s Bridge Over Troubled Water has been votedas the UK’s number one #HopeHit ― as part of UK for UNHCR’s ‘Hope on Repeat’ campaign, raising awareness of the hardships facing refugees across the globe this winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119165712/en/ Simon & Garfunkel's Bridge Over Troubled Water voted the UK's number one #HopeHit With 10% of the public vote, Bridge Over Troubled Water emerged as the UK’s most popular #HopeHit. Since November, the UN Refugee Agency’s national charity partner has invited people to nominate their #HopeHits - the tunes that connect us and warm our hearts as the weather gets cold
Prodalim Expands SOLOS Capabilities with New Dealcoholization Site in Spain19.1.2026 08:33:00 CET | Press release
Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its SOLOS division with the opening of a dedicated dealcoholization and aroma recovery site in Valencia, Spain. The new facility is fully operational and strengthens Prodalim’s ability to support the rapidly growing no- and low-alcohol (NoLo) beverage market across Europe. During the coming months, an additional SOLOS site in California is planned to be inaugurated, further expanding overall capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118626123/en/ Inauguration of the SOLOS Valencia Site for Advanced NoLo Solutions The global NoLo category continues to expand, driven by consumer demand for mindful drinking and healthier lifestyle choices. Industry forecasts estimate the NoLo global market at approximately USD 25 billion in 2025, with expected annual growth of 8–10% as the category expands across beers, win
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer19.1.2026 08:30:00 CET | Press release
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significantly improved progression-free survival versus current first-line standard of care in HER2 positive metastatic breast cancer The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY
Syngenta to Address Global Agricultural Challenges at WEF, Championing AI to Empower Farmers and Create Open Technology Access19.1.2026 08:00:00 CET | Press release
AI and digital tools are unlocking unprecedented opportunities to strengthen farms and secure food security. New IPSOS study reveals technology adoption gap, underscoring urgent need for equitable technology access. Syngenta champions "Agricultural Intelligence" at World Economic Forum, showcasing Cropwise AI solutions that put cutting-edge tools in the hands of all farmers, especially smallholders. As farmers globally grapple with unprecedented economic, geopolitical, and environmental pressures; the agricultural sector faces a continued contraction. An alarming decrease in active farms worldwide and rising financial distress underscore the urgent need for innovation and technology to ensure a resilient food system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118646017/en/ Jeff Rowe, Syngenta Group CEO "Farmers today are navigating one of the most complex periods in modern agriculture, facing pressures that demand urg
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom